Highlights Calithera Biosciences, Inc.

Equities

CALA

US13089P5070

Market Closed - OTC Markets Other stock markets 15:36:06 28/06/2024 BST			5-day change	1st Jan Change
0.01 ^USD	0.00%		-20.00%	-66.67%

2023	Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease	CI
2023	North American Morning Briefing : Stock Futures -2-	DJ

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Calithera Biosciences, Inc. Launches the Cala kIQ System, Offering Meaningful Tremor Relief for Patients with Essential Tremor and Now Parkinson’s Disease	14/06/23	CI
North American Morning Briefing : Retail Sales, -2-	16/05/23	DJ
Calithera Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
Antengene Signs Assignment Deal with Calithera to Acquire Rights on Cancer Tumor Drug; Shares Climb 10%	05/01/23	MT
Antengene Corporation Limited Enters into Assignment Agreement with Calithera Biosciences, Inc. to Acquire All Outstanding Rights of ATG-037	04/01/23	CI
Calithera Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Calithera Biosciences Receives FDA's Fast Track Designation for Lung Cancer Drug Candidate; Shares Climb	03/10/22	MT
Calithera Biosciences, Inc. Receives U.S. Food & Drug Administration Fast Track Designation for Sapanisertib for the Treatment of NRF2-Mutated Squamous Lung Cancer	03/10/22	CI
Calithera Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Calithera Biosciences, Inc. Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences	13/07/22	CI
Calithera Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of Sapanisertib in Relapsed/Refractory Nrf2-Mutated Squamous Non-Small Cell Lung Cancer	06/07/22	CI
Calithera Biosciences, Inc. Announces First Patient Enrolled in Phase 2 Clinical Trial of Mivavotinib in Relapsed/Refractory non-GCB Diffuse Large B-Cell Lymphoma	23/06/22	CI
Calithera Biosciences to Effect 1-for-20 Reverse Stock Split to Regain Compliance	14/06/22	MT
Calithera Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	10/05/22	CI
Calithera Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	31/03/22	CI
Calithera Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	31/03/22	CI
Calithera to Present Data Highlighting Newly Discovered Synthetic Lethal Target VPS4 at AACR 2022 Annual Meeting	08/03/22	CI
North American Morning Briefing : Dow Wobbles, -3-	21/01/22	DJ
Calithera Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	09/11/21	CI
Earnings Flash (CALA) CALITHERA BIOSCIENCES Posts Q3 Revenue $6.8M	09/11/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Calithera Biosciences, Inc.

Equities

CALA

US13089P5070

Highlights

Filters